NC State Spin-off TreeCo To Breed a Better Forest
A company founded by two NC State researchers is setting out to revolutionize the forestry industry by combining insights from tree genetics with the power of genome editing.
A world first: Triangle’s Locus Biosciences to launch major gene editing trial
RESEARCH TRIANGLE PARK – Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field, the company announced. Locus has opened enrollment for a Phase 1b trial of […]
NIRSleep — a startup led by an NC State alumnus, former employee — wins $25,000 in 2019 Lulu eGames
Less than four years ago, Casey Boutwell was a licensing associate for the Office of Research Commercialization, helping NC State faculty take their research from the lab into the marketplace. Now, he’s the CEO of Bionica Labs, a holding company for two […]
NIRvana Sciences Awarded $3 Million Phase IIb SBIR Grant from NIH
NIRvana Sciences, Inc., the leading developer of synthetic bacteriochlorins and chlorins, today announced that it has been awarded a $3 Million Phase IIb SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of […]
NC State Spinout Locus Biosciences Inks Historic Licensing Deal
NC State provides innovators with a range of programs and services to develop, protect, market and commercialize inventions developed at the university through the licensing of intellectual property or the launch of new companies based on university innovations. An example […]
Locus Biosciences Enters a Collaboration and License Agreement with Johnson & Johnson Innovation to develop CRISPR-Cas3 Bacteriophage Therapeutics
Locus Biosciences Inc., a biotechnology company developing precision antibacterial therapies, announced today that it has entered into an exclusive collaboration and license agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop, manufacture and commercialize CRISPR-Cas3-enhanced bacteriophage ("crPhage™") products targeting two key bacterial pathogens for the potential treatment of infections of the respiratory tract and other organ systems. Johnson & Johnson Innovation LLC facilitated the transaction.
Partner Profile: BRI Taps NC State Talent and Technology
Partnerships with NC State University’s research and academic programs have played a role in BioResource International’s success from the company’s start nearly 20 years ago – and they will in the future, as well.
Locus Biosciences acquires EpiBiome’s high-throughput discovery platform to enhance its global leadership in CRISPR-engineered phage therapeutics
Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and characterization capability with Locus’s CRISPR-based synthetic biology platform and clinical […]
Semiconductor firm HexaTech raises $2.7M in equity, wants $800,000 more
HexaTech, a spinout based on research into aluminum nitrides at North Carolina State University, is raising a new round of equity. According to a securities filing Thursday, the company has closed on $2.7 million in new cash from two investors. […]
NC State Pharma startup Emergo Therapeutics lands $12M from REX Health Ventures, Triangle backers
An all-star list of Triangle investors is backing Durham pharmaceutical startup Emergo Therapeutics with $12 million in venture capital. Leading the round, which was announced Wednesday, is REX Health Ventures. Other backers include: Wolfpack Investor Network Carolina Angel Network Hatteras Venture […]